Pneumovax 23

Browse PDR's full list of drug information

Pneumovax 23

Classes

Pneumococcal Vaccines

Administration

 
Inform the patient, parent, guardian, or responsible adult of the benefits and risks of the vaccine. Provide the Vaccine Information Statements from the manufacturer to the recipient or guardian before each immunization. These actions are required by the National Childhood Vaccine Injury Act of 1986.
Record the manufacturer and lot number of the vaccine; date of administration; and the name, address, and title of the person who administered the vaccine in the recipient's permanent medical record. These actions are required by the National Childhood Vaccine Injury Act of 1986.

Injectable Administration

Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.
Do not mix with any other vaccine.
When concomitant administration of other vaccines or immunoglobulin is required, they should be given with different syringes and at different injection sites.

Intramuscular Administration

Preparation
Use vaccine as supplied; reconstitution is not necessary.
PCV13 (Prevnar 13) and PCV20 (Prevnar 20): Shake vigorously just prior to administration to obtain a homogenous, white suspension. Do not use the vaccine if it cannot be resuspended.
PCV15 (Vaxneuvance): Shake vigorously just prior to administration to obtain an opalescent suspension. Do not use the vaccine if it cannot be resuspended.
PPSV23 (Pneumovax 23): Pneumovax 23 is a clear solution that does not require shaking prior to administration.
 
Intramuscular Injection
For vials, use a sterile syringe and needle to withdraw the vaccine from the vial. For prefilled syringes, attach a sterile needle.
Adults: Inject IM into the deltoid muscle or into the anterolateral thigh muscle.
Pediatric patients: Inject IM into the anterolateral aspect of the mid-thigh (for infants younger than 1 year) or the deltoid muscle of the upper arm (usually suitable for older children). Do NOT administer in the gluteal muscle or other areas where there may be a major nerve trunk.

Subcutaneous Administration

Only PPSV23 (Pneumovax 23) is approved for subcutaneous administration.
Use vaccine as supplied; reconstitution is not necessary. The vaccine is a clear solution.
Use a sterile syringe and needle to withdraw solution from the vial.
Inject subcutaneously into the outer aspect of the upper arm. Care should be taken to avoid intradermal injection.

Adverse Reactions
Severe

seizures / Delayed / 0-1.0
bronchospasm / Rapid / 0-1.0
skin necrosis / Early / Incidence not known
hemolytic anemia / Delayed / Incidence not known
aplastic anemia / Delayed / Incidence not known
Guillain-Barre syndrome / Delayed / Incidence not known
serum sickness / Delayed / Incidence not known
erythema multiforme / Delayed / Incidence not known
anaphylactic shock / Rapid / Incidence not known
angioedema / Rapid / Incidence not known
anaphylactoid reactions / Rapid / Incidence not known
apnea / Delayed / Incidence not known

Moderate

erythema / Early / 10.8-70.0
dyspnea / Early / 0-1.0
lymphadenopathy / Delayed / Incidence not known
thrombocytopenia / Delayed / Incidence not known
Arthus reaction / Early / Incidence not known
hypotonia / Delayed / Incidence not known

Mild

irritability / Delayed / 14.3-85.6
headache / Early / 15.9-81.4
fatigue / Early / 13.2-80.5
drowsiness / Early / 2.6-71.5
myalgia / Early / 11.9-61.8
anorexia / Delayed / 10.4-56.7
insomnia / Early / 6.8-47.7
chills / Rapid / 2.7-38.1
fever / Early / 0.3-36.5
arthralgia / Delayed / 7.7-31.5
infection / Delayed / 0.5-2.6
nausea / Early / 1.8-1.8
pruritus / Rapid / 0.2-1.6
ecchymosis / Delayed / 1.1-1.1
dyspepsia / Early / 1.1-1.1
pharyngitis / Delayed / 0.4-1.1
urticaria / Rapid / 0-1.0
back pain / Delayed / 0.9-0.9
rash / Early / 1.0
vomiting / Early / 0.9
diarrhea / Early / 0.7
malaise / Early / Incidence not known
injection site reaction / Rapid / Incidence not known
petechiae / Delayed / Incidence not known
purpura / Delayed / Incidence not known
leukocytosis / Delayed / Incidence not known
paresthesias / Delayed / Incidence not known
pallor / Early / Incidence not known
dizziness / Early / Incidence not known
syncope / Early / Incidence not known

Common Brand Names

Pneumovax 23, Prevnar 13, Prevnar 20, VAXNEUVANCE

Dea Class

Rx

Description

Multivalent vaccines against Streptococcus pneumoniae
Used for immunization against invasive pneumococcal disease and other infections caused by S. pneumoniae
Routine vaccination recommended for all geriatric patients and pediatric patients up to 5 years of age; vaccination also recommended for adults and patients 2 years and older with underlying medical conditions

Dosage And Indications
For pneumococcal prophylaxis. For routine immunization. Intramuscular dosage (PCV13 or Prevnar 13) Older Adults

ACIP does not recommend PCV13 for older adults. Vaccination with PCV20 or PCV15 (followed by a dose of PPSV23) is recommended in these patients. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Adults 18 to 64 years

ACIP does not recommend pneumococcal vaccine for healthy adults. Vaccination is only recommended for adults with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children and Adolescents 5 to 17 years at first dose

ACIP does not include recommendations for pneumococcal vaccine for healthy children and adolescents 5 years and older. Vaccination is only recommended in patients with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children 24 to 59 months at first dose

0.5 mL IM as a single dose.[39165] [53026]

Children 12 to 23 months at first dose

0.5 mL IM for 2 doses administered at least 8 weeks apart.

Infants 7 to 11 months at first dose

0.5 mL IM for 3 doses. Give the first 2 doses at least 4 weeks apart. The third dose should ideally be given after the first birthday, separated from the second dose by at least 8 weeks.

Infants 6 weeks to 6 months at first dose

0.5 mL IM for a total of 4 doses. Give the first 3 doses at intervals of 4 to 8 weeks, ideally at 2, 4, and 6 months of age; the first dose can be given as young as 6 weeks. The fourth dose is given as a booster between 12 and 15 months of age and at least 8 weeks after the third dose.

Intramuscular dosage (PCV15 or Vaxneuvance) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 1 year later.

Older Adults who previously received PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 18 to 64 years

ACIP does not recommend pneumococcal vaccine for healthy adults. Vaccination is only recommended for adults with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children and Adolescents 5 to 17 years at first dose

ACIP does not include recommendations for pneumococcal vaccine for healthy children and adolescents 5 years and older. Vaccination is only recommended in patients with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children 24 to 59 months at first dose

0.5 mL IM as a single dose. Administer a single dose to children who have received an incomplete series of another pneumococcal conjugate vaccine. At least 8 weeks should elapse between receipt of the last dose of another pneumococcal conjugate vaccine and administration of Vaxneuvance.

Children 12 to 23 months at first dose

0.5 mL IM for 2 doses, separated by at least 8 weeks.

Infants 7 to 11 months at first dose

0.5 mL IM for 3 doses. Give the first 2 doses at least 4 weeks apart. The third dose should ideally be given after the first birthday, separated from the second dose by at least 8 weeks.

Infants 6 weeks to 6 months at first dose

0.5 mL IM for a total of 4 doses. Give the first 3 doses at intervals of 4 to 8 weeks, ideally at 2, 4, and 6 months of age; the first dose can be given as young as 6 weeks. The fourth dose is given as a booster between 12 and 15 months of age and at least 8 weeks after the third dose. The 4-dose series initiated with a lower valency pneumococcal conjugate vaccine (i.e., PCV13) can be completed with Vaxneuvance.

Intramuscular dosage (PCV20 or Prevnar 20) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated.

Older Adults who previously received PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Older Adults who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Adults 18 to 64 years

ACIP does not recommend pneumococcal vaccine for healthy adults. Vaccination is only recommended for adults with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children and Adolescents 15 months to 17 years previously vaccinated with at least 1 dose of a lower valency pneumococcal conjugate vaccine

0.5 mL IM as a single dose at least 8 weeks after receipt of a lower valency pneumococcal conjugate vaccine.

Children and Adolescents 5 to 17 years at first dose


ACIP does not include recommendations for pneumococcal vaccine for healthy children and adolescents 5 years and older. Vaccination is only recommended in patients with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM dose.

Children 24 to 59 months at first dose

0.5 mL IM as a single dose.

Children 12 to 23 months at first dose

0.5 mL IM for 2 doses, separated by at least 2 months.

Infants 7 to 11 months at first dose

0.5 mL IM for 3 doses. Give the first 2 doses at least 4 weeks apart. The third dose should ideally be given after the first birthday, separated from the second dose by at least 2 months.

Infants 6 weeks to 6 months at first dose

0.5 mL IM for a total of 4 doses. Administer at 2, 4, and 6 months of age; the first dose can be given as young as 6 weeks. The fourth dose is given as a booster between 12 and 15 months of age and at least 2 months after the third dose.

Intramuscular or Subcutaneous dosage (PPSV23 or Pneumovax 23) Older Adults

0.5 mL IM or subcutaneously as a single dose. If patient previously received a pneumococcal conjugate vaccine (PCV13, PCV15), administer at least 1 year after conjugate vaccine dose.

Adults 50 to 64 years

ACIP does not recommend pneumococcal vaccine for healthy adults. Vaccination is only recommended for adults with underlying medical conditions. The FDA-approved product labeling recommends a single 0.5 mL IM or subcutaneous dose.

For invasive pneumococcal prophylaxis in patients with high-risk conditions such as chronic heart disease, chronic lung disease (e.g., asthma treated with high-dose oral corticosteroids), and diabetes mellitus. Intramuscular dosage (PCV13 or Prevnar 13) Children 2 to 5 years of age

If 3 doses of PCV13 were received previously, give one 0.5 mL dose IM at least 8 weeks after the last PCV13 dose. If less than 3 doses of PCV13 were received previously, give 2 doses at least 8 weeks apart. Children who have received a dose of PPSV23 should also receive the recommended PCV13 doses. If not previously received, a dose of PPSV23 is needed at least 8 weeks after the last PCV13 dose.

Intramuscular dosage (PCV15 or Vaxneuvance) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 1 year later.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 1 year later. These doses do not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Intramuscular dosage (PCV20 or Prevnar 20) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Older Adults who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated. This dose does not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Intramuscular or Subcutaneous dosage (PPSV23 or Pneumovax 23) Older Adults who received previous vaccination with PPSV23 and PCV13

0.5 mL IM or subcutaneously as a single dose at least 1 year after PCV13 dose. Older adults who received original PPSV23 vaccination before age 65, should receive another PPSV23 dose at or after age 65 years if at least 5 years have elapsed since the previous dose.

Older Adults who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 1 year after PCV15 dose.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV13

0.5 mL IM or subcutaneously as a single dose at least 1 year after the last dose of PCV13. This should be followed by 1 dose at age 65 years or older and at least 5 years apart from first dose.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 1 year after PCV15 dose. These doses do not need to be repeated if given before age 65 years.

Adults 18 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

Children and Adolescents 2 to 17 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

For invasive pneumococcal prophylaxis in patients with cerebrospinal fluid leak or cochlear implant. Intramuscular dosage (PCV13 or Prevnar 13) Adults 18 years who are PCV13-naive and PPSV23-naive

0.5 mL IM as a single dose, followed at least 8 weeks later by a dose of PPSV23.

Adults 18 years old who are PCV13-naive, but received previous vaccination with PPSV23

0.5 mL IM as a single dose at least 8 weeks after the last PPSV23 dose.

Children and Adolescents 6 to 17 years who are PCV13-naive and PPSV23-naive

0.5 mL IM as a single dose, followed at least 8 weeks later by a dose of PPSV23.

Children and Adolescents 6 to 17 years who are PCV13-naive, but received previous vaccination with PPSV23


0.5 mL IM as a single dose at least 8 weeks after the last PPSV23 dose.

Children 2 to 5 years

If 3 doses of PCV13 were received previously, give one 0.5 mL dose IM at least 8 weeks after the last PCV13 dose. If less than 3 doses of PCV13 were received previously, give 2 doses at least 8 weeks apart and at least 8 weeks after the last PCV13 dose. Children who have received a dose of PPSV23 should also receive the recommended PCV13 doses. If not previously received, a dose of PPSV23 is needed at least 8 weeks after the last PCV13 dose.

Intramuscular dosage (PCV15 or Vaxneuvance) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 8 weeks later.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 8 weeks later. These doses do not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Intramuscular dosage (PCV20 or Prevnar 20) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Older Adults who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated. This dose does not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Intramuscular or Subcutaneous dosage (PPSV23 or Pneumovax 23) Older Adults who received previous vaccination with PPSV23 and PCV13

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV13 dose. Older adults who received original PPSV23 vaccination before age 65, should receive another PPSV23 dose at or after age 65 years if at least 5 years have elapsed since the previous dose.

Older Adults who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV15 dose.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV13

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13. This should be followed by 1 dose at age 65 years or older and at least 5 years apart from first dose.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV15 dose. These doses do not need to be repeated if given before age 65 years.

Adults 18 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

Children and Adolescents 2 to 17 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

For invasive pneumococcal prophylaxis in patients with immunocompromising conditions (i.e., sickle cell disease and other hemoglobinopathies, anatomic or functional asplenia, congenital or acquired immunodeficiency, HIV infection, chronic renal failure, nephrotic syndrome, malignant neoplasms, leukemias, lymphomas, Hodgkin disease, solid organ transplantation, multiple myeloma, iatrogenic immunosuppression from drug or radiation therapy). Intramuscular dosage (PCV13 or Prevnar 13) Adults 18 years who are PCV13-naive and PPSV23-naive

0.5 mL IM as a single dose, followed at least 8 weeks later by a dose of PPSV23. A second PPSV23 vaccination is recommended 5 years after the first dose of PPSV23 (Max: 2 doses of PPSV23 before age 65 years).

55134

Adults 18 years who received previous vaccination with PPSV23

0.5 mL IM as a single dose at least 8 weeks after the last PPSV23 dose. A second PPSV23 vaccination is recommended 5 years after the first dose of PPSV23 and at least 8 weeks after a dose of PCV13 (Max: 2 doses of PPSV23 before age 65 years).

Children and Adolescents 6 to 17 years who are PCV13-naive and PPSV23-naive

0.5 mL IM as a single dose, followed at least 8 weeks later by a dose of PPSV23. A second PPSV23 vaccination is recommended 5 years after the first dose of PPSV23 (Max: 2 doses of PPSV23 before age 65 years).

Children and Adolescents 6 to 17 years who received previous vaccination with PPSV23


0.5 mL IM as a single dose at least 8 weeks after the last PPSV23 dose. A second PPSV23 vaccination is recommended 5 years after the first dose of PPSV23 and at least 8 weeks after a dose of PCV13 (Max: 2 doses of PPSV23 before age 65 years).

Children 2 to 5 years


If 3 doses of PCV13 were received previously, give one 0.5 mL dose IM at least 8 weeks after the last PCV13 dose. If less than 3 doses of PCV13 were received previously, give 2 doses at least 8 weeks apart. Children who have received a dose of PPSV23 should also receive the recommended PCV13 doses. If not previously received, 2 doses of PPSV23 are needed; first PPSV23 dose at least 8 weeks after the last PCV13 dose and second PPSV23 dose 5 years later.

Intramuscular dosage (PCV15 or Vaxneuvance) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 8 weeks later.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 8 weeks later. These doses do not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Intramuscular dosage (PCV20 or Prevnar 20) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least at least 1 year after receipt of PPSV23. No further doses are needed.

Older Adults who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated. This dose does not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Intramuscular or Subcutaneous dosage (PPSV23 or Pneumovax 23) Older Adults who received previous vaccination with PPSV23 and PCV13

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV13 dose. Older adults who received original PPSV23 vaccination before age 65, should receive another PPSV23 dose at or after age 65 years if at least 5 years have elapsed since the previous dose. For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

Older Adults who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV15 dose. For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV13

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13. A second PPSV23 vaccination is recommended 5 years after the first dose of PPSV23 (Max: 2 doses of PPSV23 before age 65 years). For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after PCV15 dose. These doses do not need to be repeated if given before age 65 years. For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

Adults 18 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13. A second vaccination is recommended 5 years after the first dose of PPSV23 (Max: 2 doses of PPSV23 before age 65 years). For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

Children and Adolescents 2 to 17 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13. A second vaccination is recommended 5 years after the first dose of PPSV23 (Max: 2 doses of PPSV23 before age 65 years). For patients with HIV and CD4 counts less than 200 cells/mm3, the PPSV23 can be offered; however, it may be beneficial to wait until the CD4 count increases to more than 200 cells/mm3.

For invasive pneumococcal prophylaxis in patients with chronic liver disease, alcoholism, or cigarette smoking. Intramuscular dosage (PCV15 or Vaxneuvance) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 1 year later.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose, followed by 1 dose of PPSV23 at least 1 year later. These doses do not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Intramuscular dosage (PCV20 or Prevnar 20) Older Adults who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated.

Older Adults who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Older Adults who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Adults 19 to 64 years who have never received a pneumococcal vaccine or unknown vaccine history

0.5 mL IM as a single dose. If PCV20 is used, a dose of PPSV23 is NOT indicated. This dose does not need to be repeated if given before age 65 years.

Adults 19 to 64 years who received previous vaccination with PPSV23 but who have not received any pneumococcal conjugate vaccine (PCV13, PCV15, PCV20)

0.5 mL IM as a single dose at least 1 year after receipt of PPSV23. No further doses are needed.

Adults 19 to 64 years who received previous vaccination with PCV13 but with incomplete PPSV23 series

0.5 mL IM as a single dose if PPSV23 is not available.

Intramuscular or Subcutaneous dosage (PPSV23 or Pneumovax 23) Older Adults who received previous vaccination with PPSV23 and PCV13


0.5 mL IM or subcutaneously as a single dose, given at least 1 year after PCV13 dose. Patients who received original PPSV23 vaccination before age 65, should receive another PPSV23 dose at or after age 65 years if at least 5 years have elapsed since the previous dose.

Older Adults who received previous vaccination with PCV15

 0.5 mL IM or subcutaneously as a single dose, given at least 1 year after PCV15 dose.

Adults 19 to 64 years who are PPSV23-naive and received previous vaccination with PCV13

0.5 mL IM or subcutaneously as a single dose, given at least 1 year after PCV13 dose. This should be followed by 1 dose at age 65 years or older and at least 5 years from previous dose.

Adults 19 to 64 years who are PPSV23-naive who received previous vaccination with PCV15

0.5 mL IM or subcutaneously as a single dose, given at least 1 year after PCV15 dose. These doses do not need to be repeated if given before age 65 years.

Adults 18 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

Children and Adolescents 6 to 17 years who are PPSV23-naive

0.5 mL IM or subcutaneously as a single dose at least 8 weeks after the last dose of PCV13.

For otitis media prophylaxis in infants and children younger than 6 years. Intramuscular dosage (PCV13 or Prevnar 13) Children 24 to 71 months at first dose

0.5 mL IM for 1 dose prior to the sixth birthday. The FDA-approved product labeling recommends a single dose for patients 15 to 71 months of age whereas the ACIP recommends a single dose for all children 14 to 59 months of age and for all children 60 to 71 months of age with underlying medical conditions.

Children 12 to 23 months at first dose

0.5 mL IM for 2 doses administered at least 2 months apart.

Infants 7 to 11 months at first dose

0.5 mL IM for 3 doses. Give the first 2 doses 4 to 8 weeks apart. The third dose should ideally be given at 12 to 15 months; it must be separated from the second dose by 2 months or more and given after the first birthday.

Infants 6 weeks to 6 months at first dose


0.5 mL IM for a total of 4 doses. Give the first 3 doses at intervals of 4 to 8 weeks, ideally at 2, 4, and 6 months of age; the first dose can be given as young as 6 weeks. The fourth dose is given as a booster between 12 to 15 months of age and at least 8 weeks after the third dose.

Intramuscular dosage (PCV20 or Prevnar 20) Children 24 to 71 months at first dose

0.5 mL IM as a single dose.

Children 12 to 23 months at first dose


0.5 mL IM for 2 doses, separated by at least 2 months.

Infants 7 to 11 months at first dose

0.5 mL IM for 3 doses. Give the first 2 doses at least 4 weeks apart. The third dose should ideally be given after the first birthday, separated from the second dose by at least 2 months.

Infants 6 weeks to 6 months at first dose

0.5 mL IM for a total of 4 doses. Administer at 2, 4, and 6 months of age; the first dose can be given as young as 6 weeks. The fourth dose is given as a booster between 12 and 15 months of age and at least 2 months after the third dose.

Dosing Considerations
Hepatic Impairment

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

Renal Impairment

Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.

Drug Interactions

Acetaminophen: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Aspirin, ASA; Caffeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Aspirin: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Aspirin; Diphenhydramine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Caffeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Caffeine; Dihydrocodeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Caffeine; Pyrilamine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Chlorpheniramine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Chlorpheniramine; Dextromethorphan: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Chlorpheniramine; Phenylephrine : (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Codeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan; Doxylamine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan; Guaifenesin; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan; Phenylephrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dextromethorphan; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Dichloralphenazone; Isometheptene: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Diphenhydramine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Guaifenesin; Phenylephrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Hydrocodone: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Ibuprofen: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Oxycodone: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Pamabrom; Pyrilamine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Phenylephrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Acetaminophen; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Amlodipine; Celecoxib: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Butalbital; Caffeine: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Caffeine: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Caffeine; Orphenadrine: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Carisoprodol: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Carisoprodol; Codeine: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Dipyridamole: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Omeprazole: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Aspirin, ASA; Oxycodone: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Benzhydrocodone; Acetaminophen: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Bupivacaine; Meloxicam: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Butalbital; Acetaminophen: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Butalbital; Acetaminophen; Caffeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Butalbital; Acetaminophen; Caffeine; Codeine: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Butalbital; Aspirin; Caffeine; Codeine: (Moderate) Concomitant administration of antipyretics, such as aspirin, ASA, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Celecoxib: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Celecoxib; Tramadol: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Chlorpheniramine; Ibuprofen; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Deucravacitinib: (Moderate) Patients receiving immunosuppressant medications may have a diminished vaccine response. When feasible, administer indicated vaccines at least two weeks prior to initiating immunosuppressant medications. If vaccine administration is necessary, consider revaccination following restoration of immune competence. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure after receiving the vaccine.
Diclofenac: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Diclofenac; Misoprostol: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Diflunisal: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Diphenhydramine; Ibuprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Diphenhydramine; Naproxen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Elivaldogene Autotemcel: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to non-live vaccines. When feasible, administer indicated vaccines at least six weeks prior to initiating immunosuppressant medications. If vaccine administration is necessary, consider revaccination following restoration of immune competence. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure after receiving the vaccine.
Etodolac: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Fenoprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Flurbiprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Hydrocodone; Ibuprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ibuprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ibuprofen; Famotidine: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ibuprofen; Oxycodone: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ibuprofen; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Indomethacin: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ketoprofen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ketorolac: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Meclofenamate Sodium: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Mefenamic Acid: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Meloxicam: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Nabumetone: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Naproxen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for tr

eatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Naproxen; Esomeprazole: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Naproxen; Pseudoephedrine: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Nonsteroidal antiinflammatory drugs: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ocrelizumab: (Moderate) Administer all non-live vaccines at least 2 weeks before ocrelizumab initiation, whenever possible. Ocrelizumab may interfere with the effectiveness of non-live virus vaccines. Attenuated antibody responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide and pneumococcal conjugate vaccines, and seasonal influenza vaccine were observed in patients exposed to ocrelizumab at the time of vaccination during an open-label study. Infants born to mothers exposed to ocrelizumab during pregnancy may receive non-live vaccines as indicated before B-cell recovery; however, consider assessing the immune response to the vaccine. ACIP recommends that patients receiving any vaccination during immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated a minimum of 3 months after discontinuation of therapy. Passive immunoprophylaxis with immune globulins may be indicated for immunocompromised persons instead of, or in addition to, vaccination.
Ofatumumab: (Major) Administer all needed non-live vaccines according to immunization guidelines at least 2 weeks before initiation of ofatumumab. Ofatumumab may interfere with the effectiveness of inactivated vaccines due to its actions, which cause B-cell depletion.
Oxaprozin: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Piroxicam: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Satralizumab: (Major) Administer all non-live vaccines according to immunization guidelines at least 2 weeks before initiation of satralizumab.
Siponimod: (Moderate) Administer all non-live vaccines at least 2 weeks before siponimod initiation, whenever possible. Vaccines may be less effective if given during siponimod treatment. Patients should be considered unimmunized if vaccinated within a 14-day period before starting immunosuppresive therapy or during immunosuppressive therapy, and should they be revaccinated at least 3 months after therapy is discontinued if immune competence is restored.
Sulindac: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Sumatriptan; Naproxen: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Tolmetin: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Tramadol; Acetaminophen: (Moderate) Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.
Ublituximab: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to non-live vaccines. When feasible, administer indicated vaccines at least two weeks prior to initiating immunosuppressant medications. If vaccine administration is necessary, consider revaccination following restoration of immune competence. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure after receiving the vaccine.
Valdecoxib: (Moderate) Concomitant administration of antipyretics, such as nonsteroidal antiinflammatory drugs (NSAIDS), may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar 13. Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment. However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen.

How Supplied

Pneumovax 23 Intramuscular Inj Sol
Pneumovax 23 Subcutaneous Inj Sol
Prevnar 13/Prevnar 20/VAXNEUVANCE Intramuscular Inj Susp

Maximum Dosage
Adults

0.5 mL/dose IM for PCV13 (Prevnar 13), PCV20 (Prevnar 20), and PCV15 (Vaxneuvance); 0.5 mL/dose IM or subcutaneously for PPSV23 (Pneumovax 23).

Geriatric

0.5 mL/dose IM for PCV13 (Prevnar 13), PCV20 (Prevnar 20), and PCV15 (Vaxneuvance); 0.5 mL/dose IM or subcutaneously for PPSV23 (Pneumovax 23).

Adolescents

0.5 mL/dose IM for PCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20); 0.5 mL/dose IM or subcutaneously for PPSV23 (Pneumovax 23).

Children

2 to 12 years: 0.5 mL/dose IM for PCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20); 0.5 mL/dose IM or subcutaneously for PPSV23 (Pneumovax 23).
1 year: 0.5 mL/dose IM for PCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20); safety and efficacy have not been established for PPSV23 (Pneumovax 23).

Infants

6 weeks to 11 months: 0.5 mL/dose IM for PCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20); safety and efficacy have not been established for PPSV23 (Pneumovax 23).
1 to 5 weeks: Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Mechanism Of Action

The high virulence of the pneumococcal organism is largely due to its polysaccharide capsule, which inhibits phagocytosis by white blood cells. There are at least 90 known pneumococcal capsular types. The preponderance of pneumococcal disease, however, is caused by only a minority of these 90 types. Surveillance data revealed that 56% of all deaths due to pneumococcal pneumonia at a New York medical center from 1952 to 1962 were caused by only 6 different capsular types and that 78% of all pneumococcal pneumonias were caused by 12 capsular types. A similar pattern has been demonstrated throughout the world.
 
Non-conjugate pneumococcal vaccine, polyvalent: Non-conjugated polyvalent pneumococcal vaccines (Pneumovax 23) contain the capsular polysaccharides from the 23 most virulent and common strains of pneumococcus. The vaccines include the 6 most-commonly virulent serotypes: 6B, 9V, 14, 19A, 19F, and 23F. These 23 antigens represent roughly 90% of the reported types associated with clinical infection. Studies in humans have demonstrated the immunogenicity of each of the 23 antigens when tested in polyvalent vaccines; although, some of the serotypes are reported to be poor immunogens. Non-conjugated polysaccharide vaccines stimulate a T-cell independent immune response. Vaccine exposure stimulates the immune system to produce pneumococcal capsule-specific antibodies that make the organism more vulnerable to phagocytosis and other host-defenses. The antibody produced by these vaccines is primarily IgM, which affects vaccine efficacy. They do not induce T-cell dependent responses associated with immunologic memory. After revaccination, antibody titers increase, but an anamnestic response does not occur. Clinical trials suggest a protective efficacy of 60% to 90%.
 
Conjugated pneumococcal vaccine: Prevnar 13 is a 13-valent conjugate vaccine that contains 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Serotype 1 has been reported to be the most common cause of pneumococcal empyema (24% to 50% of cases), and serotype 19A is reported to be the most common cause of invasive pneumococcal disease since the introduction of Prevnar into the childhood immunization series. Vaxneuvance is a 15-valent conjugate vaccine that contains 15 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F). Prevnar 20 is a 20-valent conjugate vaccine that contains 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F).
 
The polysaccharides of the pneumococcal serotypes are bound to a non-toxic diphtheria protein known as CRM197. By coupling the polysaccharides to this carrier protein, a T-cell dependent immune response is generated. The conjugated polysaccharide (antigen) can then be presented by major histocompatibility complex molecules, which signals the activation of T-helper cells. The T-helper cells are then able to stimulate B-cells to mature into antibody-secreting plasma or memory cells. The exposure to the vaccine produces pneumococcal capsule-specific antibodies that make the organism more vulnerable to phagocytosis and other host-defenses.

Pharmacokinetics

Pneumococcal vaccine is administered intramuscularly. The PPSV23 (Pneumovax 23) formulation of the vaccine may be administered intramuscularly or subcutaneously. The distribution, metabolism, and excretion of the vaccines have not been well-defined. The immunologic response and duration of immunity conferred by pneumococcal vaccine is dependent upon the serotypes present in the vaccine and whether the polysaccharides are coupled/conjugated to various carrier proteins. In some individuals, immune response to the vaccine may not be sufficient to prevent pneumococcal infection.
 
PCV13 (Prevnar 13): Patients who received Pneumovax 23 within 1 year prior to Prevnar 13 receipt experienced diminished immune responses to Prevnar 13 compared to Pneumovax 23 naive individuals.
PCV15 (Vaxneuvance): Immune response to Vaxneuvance was similar to that seen after Prevnar 13 administration in clinical studies, including patients administered Pneumovax 23 six months to 1 year after Vaxneuvance or Prevnar 13.
PCV20 (Prevnar 20): Patients who received Pneumovax 23 within 1 to 5 years prior to Prevnar 20 receipt experienced diminished immune responses to Prevnar 20 compared to patients who received Prevnar 13 at least 6 months prior and compared to patients who received Prevnar 13 followed by Pneumovax 23, with the last dose of Pneumovax 23 given at least 1 year prior to Prevnar 20.
PPSV (Pneumovax 23): Immunity after injection occurs in 2 to 3 weeks. Antibodies against the vaccine serotypes develop in more than 80% of vaccinated healthy adults; older adults and patients with chronic illness or immunodeficiency may not respond well. Serotype-specific antibodies decline after 5 to 10 years; however, the rate of decline varies depending on the patient population. In healthy adults, increased antibody concentrations exist for at least 5 years. Data from 1 epidemiologic study suggest vaccination may provide protection for at least 9 years after the initial dose in adults; however, the correlation between serology and clinical protection is not firm. There is some evidence that revaccination can raise antibody concentrations and can ensure life-long immunity without significantly increasing the risk of adverse reactions. Revaccination is recommended for certain patients, such as those with immunosuppression.

Pregnancy And Lactation
Pregnancy

Available data on pneumococcal vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. No adequate and well-controlled studies have been conducted in pregnant women. No fetal malformations were noted after administration of pneumococcal conjugate vaccine 13 (PCV 13) at a dose approximately 20 times the human dose to rabbits prior to mating and during gestation. According to the Advisory Committee on Immunization Practices (ACIP), administration of inactivated vaccines to pregnant women has not resulted in adverse effects in the fetus. The ACIP recommends vaccination during pregnancy when the likelihood of disease exposure is high, potential infection would cause harm to mother or fetus, and when the vaccine is unlikely to cause harm.

Data are limited regarding use of the pneumococcal vaccine during breast-feeding and its excretion in human breast milk is unknown. According to the Advisory Committee on Immunization Practices (ACIP), inactivated vaccines pose no risk for mothers or their infants. Additionally, breast-feeding does not adversely affect immunization; limited data suggest breast-feeding may enhance the immune response to certain vaccine antigens. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.